Bentley to manufacture insulin products at Cardinal Health facility

By Elaine Rigoli

Tampa, Fla., Sept. 19 - Bentley Pharmaceuticals, Inc. has secured capacity at Cardinal Health's new North Raleigh, N.C., facility for the scale-up and manufacture of clinical supplies of Bentley's intranasal insulin product candidate, facilitating the expansion of clinical trials.

The product candidate uses Bentley's proprietary CPE-215 drug-delivery technology to deliver insulin directly through diabetic patients' nasal mucosa using a small, discreet nasal spray.

The conventional treatment requires intramuscular injections several times a day, the Exeter, N.H., specialty pharmaceutical company said in a news release.

Cardinal Health is a provider of products and services supporting the health care industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.